NCT02886585: Pembrolizumab In Central Nervous System Metastases

NCT02886585
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Radiation therapy, Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients with untreated spinal cord or brainstem metastases are eligible if lesions are small & asymptomatic; Patients will be divided into 3 cohorts: untreated brain metastases, progressive brain metastases, & carcinomatous meningitis
Exclusions: Patients with untreated HER2++ primary breast cancer
https://ClinicalTrials.gov/show/NCT02886585

Comments are closed.

Up ↑